Hangzhou's draft 15th Five-Year financial development plan seeks designation as a pilot city for AI application in the financial industry and aims to accelerate AI commercialization in finance. The plan promotes fintech clustering, encourages financial institutions and major tech firms to establish fintech R&D centers and innovation platforms in the city, and calls for a digital public-service platform for the securities and futures sector. It supports multi-party fintech joint labs and incubato

2026-09-01

Hangzhou's draft 15th Five-Year financial development plan seeks designation as a pilot city for AI application in the financial industry and aims to accelerate AI commercialization in finance. The plan promotes fintech clustering, encourages financial institutions and major tech firms to establish fintech R&D centers and innovation platforms in the city, and calls for a digital public-service platform for the securities and futures sector. It supports multi-party fintech joint labs and incubators and backs financial institutions and fintech firms to develop AI+finance core and frontier technologies to generate leading IP. The plan also proposes a data‑element finance initiative that, leveraging a Hangzhou corpus, would build a trusted financial-data space to supply high-quality financial text/corpus and drive AI industry applications in finance.

其他消息
2026-08-31

China's Ministry of Industry and Information Technology (MIIT) issued a notice launching a program to cultivate AI application service providers. It directs providers to strengthen links with national computing-network hubs, national compute-interconnection nodes and the China computing platform, and to use 'compute coupons' and other policy tools to reduce compute costs. MIIT also calls for optimizing intelligent programming tools to boost software supply, opening APIs or trial access to scenar

2026-08-31

Hengrui Medicine said a pre-specified interim analysis of the pivotal Phase III trial of its HER2-targeting antibody–drug conjugate SHR-A1811 for first-line HER2‑positive recurrent/metastatic breast cancer met the primary endpoint of progression-free survival (PFS) in both randomized arms, showing statistically significant and clinically meaningful improvement versus standard docetaxel+trastuzumab+pertuzumab (THP). SHR-A1811, with or without pertuzumab, significantly extended first-line PFS vers